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1 INTRODUCTION 
1.1 Ultraviolet radiation 
Ultraviolet (UV) radiation has been used for decades with great success and a constantly 
increasing rate in the management of skin diseases. UV light is a form of electromagnetic 
radiation situated in the wavelength spectrum 100-400 nm. The UV region above 200 nm has 
been artificially subdivided on the basis of the responses of human skin and the wavelengths 
contained in sunlight. Three regions are recognized. UVC radiation (200-280 nm) is not found 
in sunlight at the surface of the earth, as it is filtered out by ozone and water vapour in the 
atmosphere. UVB radiation (280-320 nm) is the most biologically active waveband of UV 
radiation in sunlight. UVA radiation (320-400 nm) is biologically less active than UVB and 
only partially is responsible for the sun-induced erythema. 
1.2 Evolution of ultraviolet phototherapy 
The beneficial effects of sunlight for various cutaneous disorders have been known since 
antiquity. The first artificial light source, in the form of a carbon arc, was used for the 
treatment of lupus vulgaris by Niels Finsen in 1903 (Brodthagen, 1979). This was replaced by 
the hot quartz mercury vapour lamp used by Goeckerman in 1925 for daily UV light 
treatment in conjunction with crude coal tar, and with anthralin by Ingram in the 1950s 
(Goeckerman, 1925). The next advance was the development of the fluorescent lamp in the 
1960s, consisting of a low-pressure mercury vapour lamp coated with a phosphor that absorbs 
the 254 nm radiation, which is re-emitted at longer wavelengths in a continuous spectrum. 
The availability of high-intensity fluorescent UV irradiators for UVB and subsequently 
psoralen plus UVA (PUVA) therapy gave impetus to the first-line use of phototherapy for 
cutaneous disorders (Abel, 1999). 
UVA therapy utilizes light energy with a bandwidth from 320 nm to 400 nm. It can be used 
on its own as UVA radiation or in combination with psoralen. Topical administration of 
extracts and parts of plants that contain natural psoralen followed by exposure to sunlight has 
been used as a remedy for vitiligo for thousands of years, beginning with the ancient Egyptian 
and Indian healers. In modern medicine, the first studies in vitiligo with topical and oral 
psoralens were performed originally by El Mofty in 1948, and later by Lerner et al (Pathak, 
1992). In 1974, orally administered 8-methoxypsoralen (8-MOP) and subsequent irradiation 
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with UVA was a highly effective treatment for psoriasis. This new therapeutic concept was 
termed photochemontherapy or PUVA (Parrish, 1974). Within a few years the efficacy of 
PUVA were documented worldwide (Wolff, 1975). This form of therapy is currently used in 
the treatment of different skin diseases (Abel, 1999). Psoralens can be administered orally or 
applied topically in the form of solutions, creams or baths. UVA sources commonly used are 
fluorescent lamps or high-pressure metal-halide lamps. The typical fluorescent PUVA lamp 
has an emission peak at 352 nm and emits approximately only 0.5 percent in the UVB range. 
Several investigators have reported the influence of wavelength on therapeutic efficacy in 
phototherapy, mainly with regard to psoriasis (Parrish, 1981). In 1976 Fisher found 
wavelength of 313 nm more effective than longer wavelengths in the UVA region. Initially, 
broad-band (BB)-UVB light sources were applied which emit wavelengths throughout the 
whole spectrum of UVB light (280-320 nm). In 1981 Parrish and Jaenicke determined an 
action spectrum for phototherapy of psoriasis (Parrish, 1981). The most effective wavelengths 
were between 295 and 313 nm; the therapeutic effectiveness in that range resembled the 
erythemal action spectrum, peaking near 300 nm. These seminal observations provided the 
rationale for the development of more selective UVB phototherapy (SUP) irradiation devices 
(Paul, 1983). These units have a spectrum that is still broadband UVB but is enhanced in the 
range of 300 to 320 nm. A major breakthrough was achieved by the development of the 
Philips TL-01 fluorescent lamp, emitting a narrow UV band at 311-313 nm and thereby 
matching closely the assumed therapeutic optimum for psoriasis. A large number of clinical 
trials comparing BB-UVB versus 311 nm UVB phototherapy for psoriasis have been 
conducted (Coven, 1997). Based on these studies, it is now generally accepted that narrow-
band (NB)-UVB therapy is superior to BB-UVB for psoriasis (Coven, 1997). Patients treated 
with 311 nm spectrum show faster clearance of skin lesions, fewer episodes of excessive 
erythema, and a longer period of remission. For these reasons, 311 nm UVB therapy current 
represents the phototherapeutic modality of choice for the treatment of psoriasis in Europe, 
and is being used increasingly in the United States. Over the past few years, the development 
of irradiation devices with new emission spectra has led to an expanded role for phototherapy 
in the treatment of skin diseases: psoriasis, atopic dermatitis (AD), polymorphic light 
eruption, mycosis fungoides (MF), pruritus, viltiligo, lichenoid graft versus host reaction. 
5 
1.3 The xenon chloride excimer laser 
Earlier, we observed that supraerythemogenic fluences of UVB result in faster clearing of 
psoriasis, however, the limiting factor for the use of such high fluences lies with the 
intolerance of the uninvolved surrounding skin, since psoriatic lesions can often withstand 
much higher UV exposure. Because the laser light can be selectively directed towards lesional 
skin, and all of the energy of a 308 nm excimer laser is emitted within the action spectrum for 
the phototherapy of psoriasis, our group investigated the therapeutic effect of the 308 nm 
xenon chloride (XeCl) excimer laser for psoriasis. This laser emits its total energy at 308 nm 
and may therefore be regarded as a "super narrow band" UVB light source. The laser has been 
used to treat skin tumors and tattoos. In six patients with chronic plaque type psoriasis, we 
compared the efficacy of NB-UVB with 308 nm UVB laser. The number of treatments up to 
complete clearance with the NB-UVB was 29-33, while that with the XeCl laser was 8-10. 
The cumulative doses were 26-32 J/cm2, and 2.5-8.1 J/cm2 for the NB-UVB and XeCl laser, 
respectively, so the cumulative dose required for the complete clearance of psoriatic plaques 
was 6 times less with the XeCl laser than with NB-UVB phototherapy (Bonis, 1997). No 
serious side-effects were observed, just erythema, blisters, hyperpigmentation, but they were 
well tolerated. In summary, XeCl laser might therefore be regarded as a new and promising 
form of UVB phototherapy, which seems to be superior to conventional UVB sources in the 
treatment of psoriasis (Spann, 2001; Kemeny, 2001). The clinical efficacy of the XeCl laser in 
psoriasis is therefore well documented, but in other skin diseases has not been investigated so 
1.4 The mechanisms of action of ultraviolet light 
1.4.1 The mechanisms of action of ultraviolet light in T cell mediated dermatoses 
UVB and UVA phototherapy are currently regarded as modalities whose mechanism of action 
depends upon immunomodulatory effects that are not specific for a single type of light source 
(Aubin, 2003). The in vivo relevance of these immunomodulatory effects is dependent on the 
physical properties of the UV radiation employed. On a per-photon basis, wavelengths within 
the UVB spectrum possess greater energy than does UVA radiation, but because of their 
shorter wavelength, they have a more superficial depth of penetration within the skin. As a 
result, UVB phototherapy primarily affects the function of epidermal keratinocytes and 
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Langerhans cells (Takashima, 1995), whereas UVA radiation additionally affects dermal 
fibroblasts, dermal dendritic cells, endothelial cells, T lymphocytes within the dermis, mast 
cells, and granulocytes. 
UVB radiation effects the soluble mediators, e.g. it increases the interleukin (IL)-IO protein 
expression in human keratinocytes (Rivas, 1994), therefore suppresses the production of 
interferon (IFN)-y by T lymphocytes (Grewe, 1995). UVB is capable of modulating the 
expression and function of adhesion molecules, e.g. intercellular adhesion molecule-1 
(ICAM-1) expression can be efficiently prevented by exposing human keratinocytes to UVB 
radiation (Krutmann, 1990). UVB induced also down-regulation of growth factor production 
and abrogation of growth factor receptor expression (Takashima, 1995). The mixed 
lymphocyte reaction (MLR) and mixed epidermal cell lymphocyte reaction (MECLR) showed 
that the alloactivating capacity of cells was decreased by UVB exposure (Vermeer, 1994). 
UVB can also be immunosuppressive possibly at the level of antigen-presenting dendritic 
cells (Hart, 2000). The results of some new investigations provide evidence that UVB 
irradiation can induce regulatory/suppressor T cells (Aubin, 2003). According to the 
observations of Krueger et al, UVB treatment produced consistent and profound depletion of 
T lymphocytes from psoriatic epidermis. T cell activation appeared to be decreased even 
further, as judged by expression of the IL-2 receptor. Dermal lymphocytes were much less 
affected (Krueger, 1995). 
In UV-irradiated skin, a distinct and well-circumscribed inflammatory erythema develops as a 
result of the activities of lipid mediators, biologically active amines, cytokines and oxygen 
free radicals (Kemeny, 1996; Kemeny, 1994). The UVB-induced erythema is due to the 
formation of DNA damage and all the other events mentioned are secondary to this. Both 
direct and indirect data suggest, that platelet-activating factor (PAF) may play a role in the 
pathomechanism of UV-induced dermatitis (Kemeny, 1996; Publ. III.). 
Both UVB and UVA radiation are highly efficient in inducing apoptosis in human cells. UVB 
treatment caused the induction of Fas ligand on keratinocytes in human epidermis (Gutierrez-
Steil, 1998). T cells, as compared with monocytes or keratinocytes, have an increased 
susceptibility to UV radiation-induced apoptosis; this mechanism is therefore, of particularly 
importance for phototherapy of T cell-mediated inflammatory (psoriasis, AD) and 
hyperproliferative (MF) skin diseases. 
In summary, the mechanisms of action of UV light in the treatment of T cell mediated 
dermatoses fall into three major categories: (1) effects on soluble mediators; (2) modulation 
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of the expression of cell surface-associated molecules; and (3) the induction of apoptosis in 
pathogenetically relevant cells. 
1.4.2 The mechanisms of action of ultraviolet light in vitiligo 
The mechanism of action of UVB light in vitiligo is not completely understood. Similar to 
PUVA therapy, NB-UVB may exert its effects in vitiligo in a two-step process, both of which 
may occur simultaneously: (1) the stabilization of the depigmentation process, and (2) the 
stimulation of residual follicular melanocytes. 
In the perilesional skin of vitiligo T lymphocytes and macrophages have been reported, which 
confirmed the involvement of cellular immunity in the pathogenesis of the disease. Well-
documented immunomodulatory effects of UV radiation can explain the stabilization of the 
local and systemic abnormal immune responses (Parsad, 2004; Fitzpatrick, 1997; Kanwar, 
2005). The action of PUVA and NB-UVB on perilesional T lymphocytes could also be the 
explanation for the therapeutic effect of these phototherapies in vitiligo (Fitzpatrick, 1997). 
In a study of the mechanism of repigmentation in vitiligo, Cui et al demonstrated that in 
normal skin, only active melanocytes were presented in the epidermis and inactive 
melanocytes were in the outer root sheaths and formed a reservoir in human skin. While in 
vitiligo the active melanocytes in the epidermis were totally missing, the inactive melanocytes 
in the outer root sheaths of hair follicles were not affected by the pathologic process (Cui, 
1991). It is likely that NB-UVB, similar to PUVA therapy, stimulates the dopa-negative, 
amelanotic melanocytes in the outer hair root sheaths, which are activated to proliferate, 
produce melanin, and migrate outwards to adjust depigmented skin, resulting in perifollicular 
repigmentation (Cui, 1991) (Fig. 1.). 
Hachiya et al observed that stem cell factor (SCF) with its receptor, c-kit, plays an important 
role in the melanocyte mitogenesis, melanogenesis and melanocyte migration, suggesting 
another possible mechanism of UVB-induced repigmentation (Imokawa, 1995; Hachiya, 
2001). During in vitro culturing, melanocytes loose their pigment production. After repeated 
UVB (4x5 mJ/cm2) irradiation the cells regain pigmentation, observed by Kormos et al 
(Kormos, 2004). 
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Figure 1. Perifollicular repigmentation in vitiligo. 
1.5 Ultraviolet phototherapy of skin diseases 
/. 5.1 Phototherapy of psoriasis 
Psoriasis is a hyperproliferative, inflammatory skin disease of multifactorial origin, affecting 
approximately 2-3% the population worldwide. In Western Europe the disease is about as 
common as diabetes mellitus. The symptoms may appear in various forms but either mild or 
severe forms of psoriasis affect the quality of life tremendously. Clinically, psoriasis is 
considered a disease of the entire skin, with the most common presentation being well 
circumscribed erythematous, scaling plaques that may be symmetrically distributed (Fig. 2.). 
The pathogenesis of the disease is not yet known, the search for the aetiology has 
concentrated on epidermal proliferation and differentiation, inflammatory changes and the 
dermal vasculature (Nickoloff, 2004). Although each of these broad areas might hold the 
answer, now it seems that skin infiltration by activated cutaneous lymphocyte-associated 
antigen-positive T cells appears to cause a complex inflammatory tissue phenotype, leading to 
the presence of activated leukocytes in skin lesions, a diverse array of cytokines produced by 
leukocytes and keratinocytes, proliferation of small blood vessels and epidermal keratinocytes 
and increased expression of leukocyte-trafficking adhesion molecules. Therefore, there is 
considerable evidence, that psoriasis vulgaris is mediated by activated T lymphocytes 
infiltrating the epidermis and the dermo-epidermal interface (Wrone-Smith, 1996). UV 
phototherapy is indicated for patients with generalized plaque, guttate psoriasis, or 
palmoplanar psoriasis who have not responded adequately to conventional therapies. The 
choice of initial treatment with UVB or PUVA is based on a history of previous response to 
treatment, skin type, severity of psoriasis, and patient considerations, including compliance 
and responsibility for observing the precautions to avoid potential side-effects. Today, NB-
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UVB (311 nm, Philips TL01 bulbs) has become a standard therapy for plaque-type and 
guttäte psoriasis(Barbagallo, 2001). 
1.5.2 Phototherapy of atopic dermatitis 
AD is a common, multifactorial, chronic and often relapsing inflammatory skin disease with 
an incidence of 10% that occurs most commonly during infancy and childhood. It is 
characterised by cutaneous erythema, severely pruritic papular and lichenified plaques, 
excoriations, cracks, erosions (Fig. 3.) and is a cause of chronic and recurrent physical and 
psychological disability. The disease is frequently associated with elevated serum 
immunoglobulin E (IgE) levels and a personal or family history of AD, allergic rhinitis, and 
asthma. The pathogenesis of AD is primarily one of a stage-related imbalance of the ratio of T 
helper (TH)1/ TH2 cells, leading to the predominance of TH2 cells and their memory 
counterparts in acute lesions with subsequent predominance of IFN-y in later stages. The 
cytokines present in involved skin as a result of this inflammatory process. In particular, IL-4, 
IL-5, IL-10, IL-13, and IFN-y elicit an immune response resulting in the up-regulation of IgE, 
recruitment and activation of mast cells, basophiles, and eosinophils. 
Management of AD entails different approaches depending on the severity, extent, and 
distribution of skin lesions. Various forms of phototherapy are quite effective for the 
treatment of AD. Specific protocols, including UVA1 at various dosages, UVAB, UVB, NB-
UVB, PUVA (either oral or bath), balneophototherapy, climatotherapy and extracorporeal 
photopheresis (ECP) have all shown promise in the treatment of AD (Scheinfeld, 2003). The 
therapeutic effectiveness of UVA1 irradiation in the management of patients with AD was 
Figure 2. Erythematous, scaling, psoriatic plaque on the elbow. 
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first evaluated in an open study in patients with acute, severe exacerbations of the disease in 
1992 by Krutman et al (Krutmann, 1992). NB-UVB therapy is effective against moderate to 
severe atopic eczema, and is well tolerated by most patients (Reynolds, 2001). 
Figure 3. Infiltrated, eczematous lesion on the elbow-joint in AD. 
1.5.3 Phototherapy of vitiligo 
Vitiligo is a common skin disease, with a prevalence of 1% to 2%, characterized by cutaneous 
white macules (Fig. 4.), that seriously affect the quality of life of the patients. The 
pathomechanism of the disease is not fully understood, according to the convergence theory, 
the coexistence of various factors might lead to the symptoms. Autoimmune mechanisms with 
an underlying genetic predisposition are the most likely cause of vitiligo, although 
neurohumoral and autocytotoxic hypotheses are alternative theories or contributing 
mechanisms. Antibodies to melanocytes have been found by immunoprecipitation in the sera 
of patients with vitiligo causes damage to melanocytes in cell cultures, suggesting that the 
antibodies present in the sera may be involved in the pathogenesis of vitiligo (Norris, 1988). 
Vitiligo patients have an increased association of known autoimmune disorders including 
thyroiditis, pernicious anaemia, Addison's disease, diabetes mellitus and alopecia areata 
(Schallreuter, 1994). Lastly, patients with metastatic melanoma may develop vitiligo 
(Nordlund, 1983). Involvement of cellular immunity has been considered because T 
lymphocytes and macrophages in perilesional skin have been reported frequently. This 
finding is consistent with a hypothesis that lesional T cells rather than circulating 
antimelanocytic antibodies may be responsible for the patchy destruction of cutaneous 
melanocytes in vitiligo (Badri, 1993). Many treatments have been described in the literature, 
but these have to be individualised not only for the particular subject, but also for different 
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body sites on the same subject. Traditional therapies include topical, intralesional and 
systemic corticosteroids, topical and oral PUVA, and more recently, NB-UVB. The latter is 
now being used more frequently for the therapy of vitiligo in both adults in children with 
satisfactory results (Njoo, 2000; Njoo, 1999; Scherschun, 2001; Tjioe, 2005) (Table 1.). 
Table 1. Treatment scheme for vitiligo (Njoo, 1999). 
Subtype of vitiligo First-choice therapy Alternative therapies 
Children 
(<12 years) 
All Topical steroids 
(and UVA) 
Local UVB (311 nm), 
topical PUVA 
Adults Localized (<2% depigmentation) Topical steroids 
(and UVA) 
Local UVB (311 nm), 
topical PUVA 
Generalized (>2% depigmentation) UVB (311 nm) PUVA 
Segmental Autologous transplantation Topical steroids 
(and UVA), UVB (311 nm) 
Lip-tip Autologous transplantation micropigmentation 
Therapy resistant an/or generalized 
(> 80% depigmentation) 
Depigmentation with bleaching 
cream and/or laser 
none 
Figure 4. Circumscribed vitiligous macule on the trunk. 
1.5.4 Phototherapy of early stage mycosis fungoides 
MF represent clinically and biologically a heterogeneous group of non-Hodgkin lymphomas. 
Malignant skin-homing T cells growing primarily in the skin give rise to several clinical 
patterns. In general, the process begins with flat lesions (macules and patches). These 
erythematous patches are often associated with inflammation and pruritus (Fig. 5.). The 
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diagnosis is elusive as the lymphomatous cells are mature helper T cells and the lesions have 
an admixture of cell types that suggest inflammatory aetiology. These nondiagnostic patches 
can persist for years. Invasion of the epidermis is typically associated with the clinical 
changes of scaling and pruritus. As the cells proliferate, lesions become firmer and more 
varied in their surface and contour. The clinical progression of the disease than proceeds at 
variable rates with the development of cutaneous nodules and tumors or erythroderma (Table 
2.). Recent advances in the understanding of the molecular and biologic behaviour of T cells 
in this disorder - the propensity of the cells to home to the skin, to function in an activated 
state, and to achieve clonal dominance - have had a tremendous influence on the development 
of treatments (Girardi, 2004). The affected T cells in MF are characterised by a predominant 
CD4+ phenotype with frequent loss of CD7 (pan-7 cell antigen) and often demonstrate T cell 
receptor rearrangement. These atypical T cells are initially epidermotropic, but can infiltrate 
the dermis, lymph nodes, bone marrow, or other systemic organs over time. 
There are three main categories of therapy in MF: (1) skin-directed therapy (SDT); (2) 
biologic response modifiers, and (3) systemic chemontherapy (Girardi, 2004; Gathers, 2002). 
Biologic response modifiers and systemic chemontherapy are used in higher stage disease and 
refractory patch- and plaque-stage disease (Girardi, 2004) (Table 3.). The accessibility of the 
lesions, along with the failures of studies demonstrate prolonged survival using more 
aggressive systemic therapy, confirms that topical therapeutic modalities are the treatment of 
choice for localized MF (Girardi, 2004). Treatment of early stage MF consists of various 
options such as topical corticosteroids, UV phototherapy, bexarotene gel, topical 
chemontherapy (nitrogen mustard) and local radiotherapy (Girardi, 2004). When treating 
patients with early stage MF it may be beneficial to start with NB-UVB therapy and, if there 
is progression or no response, switch to PUVA therapy (Diederen, 2003). 
Figure 5. Erythematous patches in early stage MF. 
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Table 2. Classic tumor-node-metastasis (TNM) staging of mycosis fungoides 
(Wiliemze, 1997). 
TNM Definition 
Tumor 1 Patches, plaques, or both involving <10% of body surface area 
T2 Patches, plaques, or both involving >10% of body surface area 
T3 One or more cutaneous tumors 
T4 Erythroderma 
NodeO Lymph nodes clinically uninvolved 
N1 Lymph nodes clinically enlarged but not histologically involved 
N2 Lymph nodes clinically nonpalpable but histologically involved 
N3 Lymph nodes clinically enlarged and histologically involved 
Metastasis 0 No visceral disease 
Ml Visceral disease 
Bone marrow 0 No circulating atypical cells (Sezary cells) 
B1 Circulating atypical cells (Sezary cells) 
Stage Definition 
IA T1N0M0 
IB T2N0M0 
1IA T1-2N1M0 
I IB T3N0-1M0 
IIIA T4N0M0 
IIIB T4N1M0 
IVA T1-4N2-3M0 
1VB n T1-4N0-3M1 
Table 3. Therapeutic options in the management of MF (Girardi, 2004). 
Limited patch-or plaque 
disease (Tl) 
Widespread patch -or 
plaque disease (T2) 
Tumors (T3) Erythroderma (T4) 
Topical steroids Phototherapy TSEB with or without RT TSEB plus ECP 
Phototherapy Nitrogen mustard Oral bexarotene Oral bexarotene 
Bexarotene gel Oral bexarotene Denileukin difitox Chlorambucil 
Nitrogen mustard Methotrexate RT Denileukin difitox 
Radiotherapy (RT) Total-skin electron-beam 
(TSEB) 
RT plus nitrogen mustard ECP 
RT plus phototherapy IFN a - 2 b 
IFN a - 2 b PUVA plus IFN a - 2 b 
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2 AIMS OF THE STUDY 
We have previously found that the 308 nm XeCl laser was more effective than the NB-UVB 
light for the treatment of psoriasis, suggesting that UVB laser might offer advantages over 
NB-UVB (Bonis, 1997). 
Setting out from the data that indicate NB-UVB phototherapy to be an efficacious and safe 
treatment modality in dermatology, we embarked on a study of targeted phototherapy using a 
308 nm XeCl laser to treat psoriasis vulgaris, focal areas of AD, vitiligo and early stage MF. 
The specific aims of our study were: 
1. To extend our previous data on the therapeutic efficacy and safety of the 308 nm XeCl laser 
for the treatment of psoriasis. 
2. To investigate the therapeutic efficacy of the XeCl laser in the treatment of AD. 
3. To investigate the therapeutic efficacy of the XeCl laser in the treatment of vitiligo. 
4. To investigate the therapeutic efficacy of the XeCl laser in the treatment of MF. 
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3 PATIENTS AND METHODS 
3.1 Investigations in psoriasis 
3.1.1 Patients 
48 plaques of 21 patients with chronic plaque type psoriasis were treated with XeCl laser 
phototherapy. Informed consent was obtained before the start of the study. Upon entry to the 
study, the patients had not been treated with systemic antipsoriatic medication for a minimum 
of 4 weeks. 
3.1.2 Irradiation 
For each patient, a minimal erythema dose (MED) was established in uninvolved, unexposed 
gluteal skin. XeCl laser therapy was given 3 times weekly until the treated plaques had 
cleared completely. The initial dose was 0.6 MED, which was increased by 20% on each 
subsequent treatment. A 308 nm XeCl excimer laser (Lambda Physics LPX 105 E, Gottingen, 
Germany) was used: its output consisted of a train of short pulses (15 nanoseconds) at 5.5 
mJ/cm2 per pulse, the size of the light spot is 3 cm x 3 cm. In two groups of patients, XeCl 
laser phototherapy was performed with different impulse intensities (0.06 mJ/cm2 and 20 
mJ/cm2) or impulse frequencies (1 Hz and 20 Hz), and the cumulative doses and the number 
of treatments up to complete clearance were determined. In five patients, symmetrical 
psoriatic plaques were irradiated with the same energy density with XeCl laser, but the 
frequency of laser impulses was 1 Hz or 20 Hz, and local psoriasis severity index (LPSI) 
scores were determined for each plaque following each treatment. LPSI is a widely used 
scoring system for assessment of severity of psoriasis. For each plaque, erythema, induration 
and desquamation are rated according to a five-point scale. The LPSI score then can vary 
from 0 to 15, with higher scores representing greater degree of psoriatic severity. 
3.1.3 Data analysis 
The comparisons were performed by bilateral comparison study and Wilcoxon signed ranks 
test. A probability level of p<0.05 was considered statistically significant. 
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3.2 Investigations in atopic dermatitis 
3.2.1 Patients 
Fifteen patients with AD entered the study after receiving full information on the procedure 
and purpose of the trial. The mean age was 17.3 years (range from 13 to 24); there were 9 
females and 6 males. The patients satisfied the diagnostic criteria of Hanifin and Rajka 
(Hanifin, 1980). They had lesions exclusively on the flexor surfaces of the upper and/or lower 
extremities. Less than 20% of the body surface was affected. A wash-out period of two weeks 
after topical corticosteroid treatment and four weeks after systemic treatment was required 
before starting phototherapy. 
3.2.2 Irradiation 
Phototesting and laser treatment were carried out with the XTRAC laser (Photomedex 
Incorporation) instrument. This is a 308 nm excimer laser based on a self-contained gas 
system of XeCl. The output is initiated by a foot switch and consists of a train of short pulses, 
delivered through a fiberoptic hand piece, with pulse repetition of up to 200 Hz. The energy 
of each light impulse is 3 mJ, with a pulse-width of 30 nanoseconds, the beam diameter is 2 
cm. The laser allows fixed fluences to be delivered, starting from 100 mJ/cm2 with 50 mJ/cm2 
increments up to a maximum dose of 2100 mJ/cm2. Prior to treatment, all patients were 
phototested in order to determine the MED of the excimer laser, by exposing the buttock to a 
geometrical dose range between 100 and 350 mJ/cm (Fig. 6.). Phototherapy was started after 
a one-week period with a topical emollient (Repair®, Yamanouchi). The initial irradiation 
dose was 50 mJ/cm2 less than the MED. The dose was increased by 50 mJ/cm2 each week. 
The laser pulses were not overlapped, and just right up to the margin of the affected areas 
were treated. The patients were treated twice weekly, never on consecutive days. The total 
treatment period was 4 weeks, for a maximum of 8 treatment sessions, but fewer if the lesions 
cleared. During the study, no additional topical or systemic treatments were allowed, with the 
exception of the Repair® emollient. The eyes were protected with UV-blocking goggles. 
We used the local eczema area severity index (EASI) to determine the severity of the AD 
(Barbier, 2004). The local EASI score is the sum of the scores of four clinical symptoms 
(erythema, infiltration, lichenification and excoriation), these being graded from 0 to 3 (0: 
absent, 1: mild, 2: moderate, 3: severe). The patients rated the intensity of itching during the 
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24-h period, using a 10-cm visual analogue scale, with 0 cm indicating "no itching" and 10 
cm indicating "worst itching imaginable". The aim of the quality of life (QL) questionnaire 
(10 questions) was to measure how much the skin problem had affected the patients (0: not at 
all, 1: mildly, 2: moderately, 3: very much) during the past week. Photographs were taken one 
week before the commencement of laser therapy and at the completion of the therapy. The 
severity of the AD was scored after the one-week wash-out period at the baseline visit, and 
then once weekly during the laser treatment. 
100 mJ/cm2 150 mJ/cm2 200 mJ/cm2 
250 mJ/cm2 300 mJ/cm2 350 mJ/cm2 
Figure 6. Determination the MED by exposing the buttock to a geometrical dose range 
between 100 and 350 mJ/cm2UVB. The MED of this patient was 150 mJ/cm2. 
3.2.3 Data analysis 
Statistical analysis were performed with Friedman's non-parametric repeated measures 
ANOVA, followed by the Student-Newman-Keuls multiple comparison procedure. A 
probability of P<0.05 was considered to be statistically significant. 
3.3 Investigations in vitiligo 
3.3.1 Patients 
Six patients with localized vitiligo were included in the study, five women and one man with 
a mean age of 27.3 years, ranging form 24 to 45 (Table 4.). Three individuals had Fitzpatrick 
skin type II and three had type III skin (Table 5.) (Astner, 2004). All of them had localized, 
stable vitiligo: three patients presented the focal subtype, three had the segmental form. The 
mean duration of the disease was 9 years, ranging from 5 to 14. All patients had been treated 
unsuccessfully with topical corticosteroids and other phototherapies before. The patients were 
without any treatment for six months prior to the study. They were otherwise healthy and used 
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3.3.3 Data analysis 
On the initial visit, a complete history and skin examination were performed. Photographs 
were taken before the first treatment, after three and six months of treatment, and three 
months following termination of the laser therapy. Improvement compared with baseline 
examination was recorded in percentage depending on the extent of repigmentation. Patient 
compliance was noted in terms of attendance frequency for treatment. 
3.4 Investigations in early stage mycosis fungoides 
3.4.1 Patients 
Four patients with limited patch-stage MF were included in the study (Table 6.). The mean 
age was 60.7 years (range from 37 to 71); there were 2 females and 2 males. In all patients, 
the diagnosis of MF was established by the clinical appearance of clinical lesions and 
confirmed histologically by conventional microscopy and immunohistochemical staining. T 
cell receptor rearrangement was examined with polymerase chain reaction (PCR). Stage of 
disease was classified based on the TNM classification (Table 2.). All of the patients had 
stage IA disease. Stage IA is MF confined to the skin with less than 10% patches and plaques 
covering the skin surface (i.e., T1N0M0 in the TNM classification). After giving informed 
consent, all patients were required to discontinue any topical treatment for at least 4 weeks, 
any systemic treatment for at least 1 month before starting laser treatment. 
Table 6. Profile of patients with MF. 
Age(y) 
/Sex 
Skin 
type 
Affected area Previous therapy TNM/Stage Duration of 
disease 
62/F III leg, trunk topical corticosteroids, PUVA, 
retinoid 
T1N0M0/IA 9 years 
53/M 11 arm topical corticosteroids, PUVA T1N0M0/IA 12 years 
71/M III trunk, leg, arm topical corticosteroids, PUVA T1N0M0/IA 10 years 
37/F III Trunk topical corticosteroids T1N0M0/IA 3 months 
20 
3.4.2 Irradiation 
Phototesting and laser treatment were carried out with the XTRAC laser (Photomedex 
Incorporation) instrument. The energy of each light impulse is 3 mJ, with a pulse-width of 30 
nanoseconds, the beam diameter is 2 cm. The laser allows fixed fluences to be delivered, 
starting from 100 mJ/cm2 with 50 mJ/cm2 increments up to a maximum dose of 2100 mJ/cm2. 
Before treatment, all patients were phototested to determine the MED of the 308 nm UVB by 
exposing an uninvolved area of skin to a dose range between 100 and 350 mJ/cm2. The 
irradiation doses were twice the MED. Treatment was administered three times or twice 
weekly until clinical clearance or minimal residual activity (improvement > 90%) was 
achieved. During the study, no additional topical or systemic treatments were allowed. 
3.4.3 Data analysis 
Clinical evaluations were performed every session. Photographs were taken before the first 
treatment and after termination of the laser therapy. Clinical response was rated as follows: 
complete remission (no disease activity present), partial remission (decrease of disease 
activity > 50%), and progressive disease (increase of disease activitiy > 25%). 
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4 RESULTS 
4.1 Results is psoriasis vulgaris 
48 plaques of 21 psoriatic patients were treated with the XeCl laser. In order to optimize 
certain parameters of the UVB phototherapy, we examined whether the therapeutically effect 
of the XeCl laser depends on the intensity and frequency of the laser impulses. 
The mean cumulative doses up to complete clearance of the psoriatic plaques were 4.06 and 
0 9 
4.05 mJ/cm for impulse intensities of 20 and 0.06 mJ/cm , respectively (data not shown); the 
mean number of treatments was 9.2 in both cases. When the XeCl treatment was carried out 
with an impulse frequency of 1 or 20 Hz, the mean cumulative doses were 4.6 and 4.3 
mJ/cm2, the mean number of treatments was 8 (data not shown). None of these differences 
proved statistically significant. When the irradiation was performed with 1 or 20 impulses/s, 
there was also no significant difference in the decrease in LPSI scores (Fig. 7/a, lib). 
Representative clinical pictures are presented in Figure 8. 
CD Pre-tr eatment 
1 Hz • Post-treatment 
Patients 
Figure 7a. The local psoriasis severity index (LPSI) scores measured before and after 
treatments with XeCl laser with 1 Hz or 20 Hz impulse frequencies. Symmetrical psoriatic 
plaques of 5 patients were compared. The initials of the patients are represented under the 
bars. 
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Figure 7b. The averagetstandard deviation of local psoriasis severity index (LPSI) scores 
measured before and after treatments with XeCl laser with 1 Hz or 20 Hz impulse 
frequencies. Symmetrical psoriatic plaques of 5 patients were compared. The differences 
proved to be statistically not significant measured by Wilcoxon signed ranks test. 
a. b. 
Figure 8. Psoriatic plaque on the leg before (a.) and after 1 month (b.) of laser treatment. 
After treatment (b.) erythema and transient hyperpigmentation was evidenced in the treated 
areas with spontaneous resolution. 
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4.2 Results in atopic dermatitis 
Of the 15 patients enrolled in the study, one was lost to follow-up because of non-compliance. 
14 patients completed the study. Representative clinical pictures are presented in Figure 9. 
Depending on the skin type and the MED, the initial doses in the individual patients ranged 
from 150 mJ/cm2to 450 mJ/cm2. The mean cumulative dose of UVB was 1.66 J/cm2. Figure 
10 shows the reduction in the intensity of erythema (10/a), infiltration (10/b), excoriation 
(10/c) and lichenification (10/d), with a mean reduction of 58%. At the completion of laser 
therapy, each score was significantly lower than the initial values. The local EASI scores are 
presented in Figure 10/e. Before the laser treatment, the EASI scores ranged between 3 and 14 
(mean 8.5). At the end of the treatment period, the EASI scores were between 0 and 15 (mean 
3.57), and significantly lower as compared with the initial values. Figure 10/f depicts the QL 
data. Before the laser treatment the QL scores ranged between 4 and 11 (mean 6.57), whereas 
at the end of the treatment period they were between 0 and 6 (mean 1.71), and significantly 
lower than the baseline values. Figure 10/g demonstrates an 81% reduction in the itching 
score after one month of phototherapy, from 2-8 (mean 5.57) to 0-4 (mean 1.02). The score 
values of erythema, infiltration, excoriation and itching significantly decreased after one week 
of treatment while the intensity of lichenification reduced after two weeks. EASI scores 
significantly decreased upon treatment showing the most dramatic decrease in the first two 
weeks. No serious or unpleasant side-effects were observed. There was no exacerbation at the 
one-month follow-up, although relapse is possible as with other phototherapies. 
Figure 9. Lesions of AD on the elbow-joint before (a.) and after 1 month (b.) of laser 
treatment. 
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b. Infiltration 
c. Excoriation 
baseline 1 2 3 4 
weeks 
d. Lichenification 
baseline 1 2 3 4 
weeks 
f. Quality of life 
Figure 10. The scores of erythema (a), infiltration (b), excoriation (c), lichenification (d), 
EASI (e), QL (f), itching (g) significantly decreased during the laser treatment. All values are 
expressed as means ± standard error. The asterisks indicate statistically significant differences 
(P<0.05) in comparison with the baseline values. 
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4.3 Results in vitiligo 
The clinical responses are presented in Table 6. Four patients have completed the six-month 
therapy, two were lost because of non-compliance after 5 weeks. Repigmentation generally 
started eight weeks after the beginning of the laser therapy, with 1-3 mm pigmented macules. 
During therapy a typical, perifollicular repigmentation was observed. After six months one 
patient responded with 95% of repigmentation, two individuals showed 75%, one showed 
repigmentation in less then 50% of the area treated. We did not find correlation between the 
therapeutic response and disease duration. There was no loss of the repigmentation at the 
three-month follow up. No phototoxic or photoallergic reactions, perilesional 
hyperpigmentation were observed. Side-effect were minimal: that included mild erythema and 
pruritus, which resolved spontaneously. No patients experienced symptoms that warranted 
discontinuation of laser therapy. Clinical pictures are presented in Fig. 11. and 12. 
Table 6. Clinical response in vitiligo patients. 
Compliance Cumulative dose (J/cnT) Repigmentation (%) Side-effects 
+ 70.8 95 mild erythema, pruritus 
+ 51.3 75 mild erythema, pruritus 
+ 49.3 75 none 
+ 31.5 <50 mild erythema 
- 3.2 - -
- 2.7 - -
Figure 11. Vitiligous macules on the face before laser therapy (a.), after 3 months of 
treatment (b.), after 6 months of laser therapy (c.). 
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Figure 12. Vitiligous macules on the elbow before laser therapy (a.), after 3 months of 
treatment (b.), after 6 months of treatment (c.). 
4.4 Results in mycosis fungoides 
Four patients were treated, all achieved complete clinical remission with a marked reduction 
in size and infiltration of the patches (Fig. 13.). Clinical healing was obtained in 6 to 14 
9 9 
sessions (average: 9), with a cumulative dose ranging from 2.8 J/cm to 7.4 J/cm (mean: 4.4 
J/cm2) (Table 7.). A slight erythema and transient hyperpigmentation was evidenced in the 
treated areas with spontaneous resolution after two weeks following the end of treatment. No 
serious or unpleasant side-effect were observed. There was no exacerbation at the six-month 
follow-up, although relapse is possible as with other phototherapies. 
Table 7. Clinical response in MF patients. 
MED 
(J/cm2) 
Cumulative dose (J/cm2) Number of sessions Treatment interval (weeks) 
200 2.8 7 4 
200 3.6 9 5 
250 7.6 14 6 
300 3.6 6 3 
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Figure 12. Vitiligous macules on the elbow before laser therapy (a.), after 3 months of 
treatment (b.), after 6 months of treatment (c.). 
4-4 Results in mycosis fungoides 
Four patients were treated, all achieved complete clinical remission with a marked reduction 
in size and infiltration of the patches (Fig. 13.). Clinical healing was obtained in 6 to 14 
2 2 
sessions (average: 9), with a cumulative dose ranging from 2.8 J/cm to 7.4 J/cm (mean: 4.4 
J/cm2) (Table 7.). A slight erythema and transient hyperpigmentation was evidenced in the 
treated areas with spontaneous resolution after two weeks following the end of treatment. No 
serious or unpleasant side-effect were observed. There was no exacerbation at the six-month 
follow-up, although relapse is possible as with other phototherapies. 
Table 7. Clinical response in MF patients. 
MED 
(J/cm2) 
Cumulative dose (J/cm2) Number of sessions Treatment interval (weeks) 
200 2.8 7 4 
200 3.6 9 5 
250 7.6 14 6 
300 3.6 6 3 
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a. b. 
Figure 13. Infiltrated MF lesions on the forearm of a patient before (a.) and after (b.) laser 
treatment. After treatment (b.) erythema and transient hyperpigmentation was evidenced in 
the treated areas with spontaneous resolution. 
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5 DISCUSSION 
5.1 Xenon chloride laser in the phototherapy of psoriasis vulgaris 
UV phototherapy is widely applied to treat different dermatoses. The prototypic skin disease 
showing a favorable response to UV phototherapy is psoriasis vulgaris (Fischer, 1976). There 
is growing evidence that the efficacy of UVA and UVB phototherapy may not simply be 
attributed to antiproliferative effects, but most likely involves immunomodulatory 
consequences (Morita, 1997; Gilmour, 1993). One of the major mechanisms of action of UVB 
light in the treatment of inflammatory dermatoses seems to be a cytotoxic effect on the 
infiltrating T cells, where the mechanism of cell death is most probably apoptosis (Ozawa, 
1999; Aragane, 1998). 
Earlier, we found that XeCl UVB laser clears psoriatic plaques more efficiently, than 
conventional NB-UVB. The cumulative dose required for the complete clearance of psoriatic 
Plaques was 6 times less with the XeCl laser than with NB-UVB phototherapy (Bonis, 1997). 
The high clinical efficacy of the XeCl laser for psoriasis was later confirmed by other studies. 
Asawanonda et al determined the dose-response relationship of XeCl laser for psoriasis. They 
used 8 different fluences from 0.5 to 16 MED. The use of such high fluences resulted in a 
prolonged remission of psoriasis, even after a single treatment. They could demonstrate that 
fluence was the single most important determinant in the clinical clearing of psoriasis 
(Asawanonda, 2000). Trehan et al also investigated the antipsoriatic efficacy of one single 
high fluence XeCl laser treatment. 11 of 14 patients showed significant improvement within 1 
month, and 5 still demonstrated persistent areas of clearing at 4 months (Trehan, 2002). 
Another studies established the high efficacy of XeCl laser in chronic inverse psoriasis 
(Mafong, 2002) and scalp psoriasis(Gupta, 2004). According to a multicenter open trial from 
5 dermatology practices including 124 patients, 84% of the patients achieved at least 75% 
clearing in after 10 or fewer treatments. No serious side-effects were observed, just erythema, 
blisters, hyperpigmentation, but they were well tolerated (Feldman, 2002). 
In order to expand our earlier pilot study, in the present study we investigated the efficacy of 
the XeCl laser for the treatment of psoriasis. All 21 patients tolerated the treatment well and 
no serious side-effects were observed. The XeCl laser phototherapy was highly effective in all 
of the treated plaques, the LPSI scores decreasing quickly following each visit (Publ. V.) 
Conventional UVB sources emit polychromatic continuous incoherent light, whereas the 
XeCl laser emits coherent, monochromatic UVB light in short impulses, which permits the 
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variation of certain important phototherapeutic parameters, such as impulse frequency and 
hght intensity. Earlier, when psoriatic skin was irradiated with multiple MED doses of XeCl 
laser, the application of higher frequency of laser impulses led to the induction of stronger 
erythema (unpublished data). These observations indicated that the frequency of impulses 
influences the biological effect of phototherapy. In the present study, we compared the 
antipsoriatic efficacy of the XeCl laser when the irradiation was performed at different 
intensities and impulse frequencies. We did not find significant differences in either of the 
investigated parameters. In our previous clinical study, treatment of psoriasis with the XeCl 
laser proved to be more effective than with NB-UVB. We therefore compared the apoptosis-
inducing capacities of two different UVB sources: the XeCl UVB laser was found to be a 
more potent inductor of T cell apoptosis than was NB-UVB light (Publ. V.) There can be 
several explanations for this difference. Although the NB-UVB light source emits most of its 
energy in the wavelength interval 311-313 nm, its emission spectrum contains longer 
wavelengths too, which may exert a less cytotoxic effect on T cells. On the other hand, the 
intensity of XeCl laser light is much higher than that of NB-UVB light: the XeCl laser emits 
its energy in nanoseconds, while the performance of NB-UVB irradiation requires minutes. 
Additionally, the higher apoptosis-inducing efficacy of the XeCl laser might be explained by 
the differences in the biological effects of coherent laser light from those of incoherent light. 
Our in vitro experiments were paralleled by the in vivo results of the use of the XeCl laser for 
the treatment of psoriasis, suggesting that the more effective induction of T cell apoptosis 
may be responsible for the greater clinical efficacy of the XeCl laser as compared with NB-
UVB light"(Publ. V.). 
Carcinogenicity of different UV therapies increases in parallel with the cumulative UV dose 
during life (Lavker, 1995). We found earlier, that the cumulative dose needed for healing was 
more than 6 times less with the XeCl laser than with NB-UVB therapy (Bonis, 1997). We 
Presumed, that the lower therapeutic cumulative dose therefore involves a lower risk of 
carcinogenesis. Additionally, as the majority of the psoriatic patients suffer from mild to 
moderate psoriasis, affecting only 10-20% of the total body surface, and the XeCl laser is 
selectively directed toward lesional skin, the laser treatment results in sparing the surrounding 
normal skin from unnecessary carcinogenic UV radiation exposure. 
In summary, our results suggest that the XeCl laser is a new and promising form of UVB 
Phototherapy, which seems to be superior to conventional UVB sources in the treatment of 
Psoriasis (Spann, 2001; Kemeny, 2001; Publ. V.). 
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5.1 Xenon chloride laser in the phototherapy of psoriasis v u l g a r i s 
The management of AD entails different approaches, depending on the severity, extent and 
distribution of the skin lesions. The mainstays of topical therapy include the regular use of 
emollients, coupled with antimicrobials, corticosteroids and immunomodulators. For severe 
disease, systemic medication such as cyclosporine A can be used for limited periods. 
Phototherapy is effective for the treatment of AD (Scheinfeld, 2003). UVA1 at various 
dosages, UVAB, UVB, NB-UVB, PUVA (either oral or bath), balneophototherapy, 
climatotherapy and ECP have all shown promise in the treatment of AD (Prinz, 1994; 
Scheinfeld, 2003; Simon, 2000). 
The most frequently applied effective forms of phototherapy include NB-UVB and PUVA in 
patients with moderate to severe AD (Der-Petrossian, 2000). Although insufficient human 
data are available, it is supposed that long-term NB-UVB therapy may involve a lower risk of 
skin cancer than that of PUVA therapy (Slaper, 1986). 
In the present study, the XeCl UVB laser proved effective for the treatment of localized AD. 
The mean cumulative dose required for the complete clearance of AD was (5 times) less with 
the XeCl laser than compared with NB-UVB therapy (Reynolds, 2001). All of our patients 
observed clinical improvement and QL improvement. The score values of erythema, 
infiltration, excoriation, lichenification and itching significantly decreased during the 
treatment. EASI scores significantly decreased upon treatment showing the most dramatic 
decrease in the first two weeks. 
In conventional phototherapy and photochemontherapy the whole body is exposed to UV 
radiation, the region of action of the 308 nm excimer laser can be restricted to the involved 
areas. The side-effects, and especially the carcinogenicity, of the different types of UV 
therapy increase with the cumulative UV dose to which a person is exposed throughout life. 
With our treatment modality, only the affected areas are treated by UVB light, so that the 
risks of carcinogenesis and other UVB side-effects occurring on the surrounding skin are 
much lower. 
Our results suggest that the xenon chloride laser is effective and well-tolerated treatment for 
localized atopic dermatitis (Publ. IV.). However, randomised clinical studies should be 
Performed to show its efficacy in combination with conventional treatment modalities. 
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5.1 Xenon chloride laser in the phototherapy of psoriasis vulgaris 
Phototherapy alone or in combination is a well-established and widely used treatment for 
vitiligo. Previously PUVA appeared to be the best method in providing reasonable hope for 
achieving repigmentation. Both topical and systemic PUVA are used, but short-term and 
long-term side-effects should be accurately evaluated. Long periods of treatment are required 
and the results are not always satisfactory. The NB-UVB phototherapy that was firs 
introduced for the treatment of psoriasis, is now widely used to treat vitiligo. Some studies 
have compared the efficacy of NB-UVB therapy to topical PUVA in treating generalized 
vitiligo, conclude that NB-UVB was as efficient as topical PUVA, but had fewer adverse 
effects (Westerhof, 1997). Based on meta-analysis of the literature it has been reported that of 
the non-surgical repigmentation techniques class 3 corticosteroids and NB-UVB therapy were 
the most effective and safest for both localized and generalized vitiligo (Njoo, 1999; Njoo, 
1998; Kanwar, 2005; Tjioe, 2005). Oral PUVA was associated with the highest rates of side-
effects, while no side-effects were reported with UVB (Njoo, 1999; Njoo, 1998). Recently 
NB-UVB has been reported effective and safe in adults and children with vitiligo (Njoo, 
2000; Scherschun, 2001). Using UVB microphototherapy, the vitiligous patches could be 
electively treated with BB-UVB light, and this BB-UVB microphototherapy might be a 
treatment of choice for patients with localized vitiligo according to the study of Lotti et al. 
(Lotti, 1999). The lack of exposure of the uninvolved skin to UV radiation results in a less 
risks of short-term and long-term side-effects such as accelerated photoaging and 
photocarcinogenesis. The 308 nm XeCl laser provide similar advantages for localized vitiligo, 
as the uninvolved skin can be excluded from the treatment. Additionally, the use of 308 nm 
XeCl laser might offer further advantages for vitiligo treatment. Although there are no 
comparative studies using different UVB light sources in vitiligo, in psoriasis NB-UVB was 
more effective than BB-UVB (Coven, 1997), and XeCl laser was found to be more effective 
than NB-UVB light (Kemeny, 2001; Bonis, 1997). Hong et al reported the 308 nm laser 
therapy more effective than NB-UVB therapy in the treatment of vitiligo (Hong, 2005). The 
greater clinical efficacy of XeCl laser compared to NB-UVB light in psoriasis might be partly 
due to its deeper penetrance into the skin, as irradiation of the psoriatic skin with XeCl laser 
induced higher number of apoptotic T cells in the dermis than with the NB-UVB light (Publ. 
V.). As repigmentation in vitiligo is probably due to the activation of melanocytes in the hair 
follicles (Feldman, 2002), the deeper penetrance of the XeCl laser might result the good 
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therapeutical results achieved with this light source. Additionally, conventional UVB sources 
emit polychromatic continuous incoherent light, while XeCl laser emits coherent, 
monochromatic UVB light in short impulses, and the biological effects of coherent laser light 
and incoherent light with the same wavelength might differ. Indeed, we could show recently, 
that irradiation of T cells with XeCl laser in vitro induced a higher number of apoptotic cells 
than obtained with the NB-UVB light in the same dosages (Publ. V.), suggesting that in 
addition to its deeper penetrance into the skin, other factors might also contribute to the 
greater clinical efficacy of the laser. 
In the present study we investigated the efficacy of the XeCl laser for the treatment of vitiligo. 
Four patients completed the six-month therapy. One patient responded with 95% of 
repigmentation, two individuals showed 75%, one showed repigmentation in less than 50% of 
the area treated. No serious side-effects were observed. We found the 308 nm XeCl laser 
useful and well-tolerated in the treatment of localized vitiligo (Publ. I., II.). The clinical 
efficacy of the XeCl laser for the treatment of vitiligo (Feldman, 2002; Taneja, 2003; Leone, 
2003; Hadi, 2004) and resurfacing-induced leukoderma (Friedman, 2001) was confirmed later 
by other studies. 
In summary, the XeCl UVB laser might therefore be regarded as a treatment of choice in the 
phototherapy of localized vitiligo. 
5.4 Xenon chloride laser in the phototherapy of early stage mycosis fungoides 
SDT is used more common in early stage MF, in which the infiltrate is characterized 
histologically by relative sparse and superficial lymphocytic accumulation. SDT is used as 
first line therapy, as adjuncts, or for maintenance (Gathers, 2002). SDT has included nitrogen 
mustard (mechlorethamine), topical carmustine, UVB, PUVA, localized radiation. The results 
of phototherapy with BB-UVB in the treatment of MF have been reported previously 
(Ramsay, 1992; Resnik, 1993; Diederen, 2003). Ramsey et al reported results from a 
retrospective study of 37 patients with histologically proven MF who were treated with BB-
UVB. Of these patients, 84% had patch-stage disease, and 13% had plaque-stage disease. Of 
these patients 71% achieved a complete remission. The median time to remission was 5 
months. None of the patients with plaque-stage disease were responsive to UVB treatment. 
Resnik et al and Vorderheid et al reported similar results in their 15-year follow-up study of 
31 patients with histologically proven cutaneous T cell lymphoma (CTCL) who were treated 
33 
with UVB (Resnik, 1993). Of these patients, 21 were classified as having stage IA disease, 9 
had stage IB disease, and 1 had stage IIA disease according to the TNM system. An objective 
clinical response was observed in 85% of the patients, with 74% achieving a complete clinical 
and histological response to therapy. The maximum duration of the remission ranged from 5 
months to more than 15 years (median: 51 months). The patients with plaque-stage disease 
tended to respond less favourably. In the study by Clark et al, 8 patients with histologically 
proven patch-stage MF were treated with NB-UVB three times weekly using a standard 
protocol (Clark, 2000). Complete clearance of MF was achieved in 6 patients in a mean of 9 
weeks or 26 treatments and 4 patients obtained prolonged remissions. Mean time to remission 
was 20 months. Partial response to NB-UVB was associated with rapid relapse. Diederen et al 
reported results from a retrospective study of 56 patients with early stage MF (stage IA and 
IB). 21 patients were treated with NB-UVB, 35 patients were treated with PUVA. NB-UVB 
treatment leads to complete remission in 81% of patients, to partial remission in 19% of 
patients, and none showed progressive disease. PUVA treatment leads to complete remission 
in 71% of patients, partial remission in 29% of patients, and none showed progressive disease. 
The mean relapse-free interval for patients treated with UVB was 24.5 months (range: 2-66 
months) and for patients treated with PUVA 22.8 months (range: 1-43 months). They 
concluded, that NB-UVB is an effective treatment for early stage MF. It has several 
advantages over treatment with BB-UVB and PUVA. When treating patients with early stage 
MF it may be beneficial to start with NB-UVB therapy and, if there is progression or no 
response, switch to PUVA therapy (Diederen, 2003). In 2004 Nistico et al reported the 308 
nm XeCl excimer laser effective in the treatment of MF. Ten lesions from five patients were 
treated until complete remission was achieved. The first treatment session started at a dose of 
twice the MED, and increased by 150-500 mJ/cm during the following sessions. The number 
of treatments varied from 4 to 10, with a 7-10 day interval according to the response of the 
patients. The cumulative doses ranged from 6 to 12 J/cnr. After 12 months follow-up the 
lesions were in complete remission. Slight erythema and transient hyperpigmentation was 
observed, which resolved spontaneously (Nistico, 2004). Passeron et al find the 308 nm XeCl 
laser effective and well tolerated in early stage MF (Passeron, 2004). 
The exact mechanism of action of NB-UVB therapy is probably due to apoptosis induction in 
malignant T cell clones. In vitro experiments show that UVB decreases the allo-activating and 
antigen-presenting capacity of Langerhans cells and increases IL-2 and IL-6 production by 
human keratinocytes (Duthie, 1999; Guckian, 1995). Increased tumor necrosis factor (TNF) 
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has also been detected after UVB irradiation. Possibly, UV light suppresses the function of 
the neoplastic population of clonal T cells in the skin and serves as an immune up-regulator 
(Duthie, 1999). 
In our study, four patients were treated and all achieved complete clinical remission with a 
marked reduction in size and infiltration of the patches. Although the number of patients is 
limited, the clinical healing observed in all 4 patients demonstrates the benefits of this new 
technique. These results are obtained rapidly, allowing a low rate of cumulative doses. More 
follow-up is needed, but, as in other studies, a prolonged period without recurrences may be 
expected. In summary, our results showed the efficacy of the 308 nm excimer laser in clearing 
localized patch-stage MF. 
6 SUMMARY 
The 308 nm XeCl laser is not unknown in dermatology. The laser emits coherent, 
monochromatic UVB light in short impulses. The laser treatment is selectively directed 
toward lesional skin and results in sparing the surrounding normal skin from unnecessary 
carcinogenic UV radiation exposure. In 1991 it has been tried to remove tattoos and skin 
tumors using its thermal coagulation effect (Loe, 1990). In 1997 we have found the XeCl 
excimer laser more effective than the NB-UVB in the treatment of psoriasis (Bonis, 1997; 
Kemeny, 2001). The clinical efficacy and safety of XeCl laser for the treatment of psoriasis 
was confirmed later by other studies (Spann, 2001; Trehan, 2002; Asawanonda, 2000; 
Feldman, 2002; Gerber, 2003; Publ. V.). In 2001 we have found the laser effective and well 
tolerated in the treatment of localized vitiligo (Publ. I., Publ. II.). The clinical efficacy of the 
XeCl laser for the treatment of vitiligo (Taneja, 2003; Hadi, 2004; Leone, 2003) was 
confirmed later by other studies. In addition, the XeCl laser was also effective in the 
phototherapy of resurfacing-induced leukoderma (Friedman, 2001), hypopigmented scars and 
striae (Goldberg, 2003; Alexiades-Armenakas, 2004). Recently we have found the XeCl UVB 
laser effective for the treatment of AD (Publ. IV.). 308 nm laser was found to be effective in 
the treatment of early stage MF (Nistico, 2004; Passeron, 2004), and also for oral lichen 
planus (Kollner, 2003; Trehan, 2004). The 308 nm XeCl laser treatment is approved by the 
Food and Drug Administration (FDA) for the treatment of psoriasis, vitiligo and AD. 
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One of the major mechanisms of action of UVB light in the treatment of different dermatoses 
seems to be a cytotoxic effect on the infiltrating T cells, where the mechanism of cell death is 
most probably apoptosis (Ozawa, 1999; Aragane, 1998). In our investigations the XeCl laser 
induced T cell apoptosis in vitro and was found to be a more potent inductor of T cell 
apoptosis than NB-UVB light (Publ. V.) 
Based - at least partly - on our investigations with the 308 nm excimer laser, a number of new 
phototherapeutical devices utilizing targeted phototherapy have been developed, and 
revolutioned the phototherapy of skin diseases. 
New results: 
1 • We extended our pervious data on XeCl laser treatment for psoriasis, and could show the 
efficacy and safety of 308 nm laser for psoriasis. The clinical efficacy did not depend on 
light intensity or on laser impulse frequency. 
2. We have shown for the first time that XeCl laser is effective for the treatment of AD. 
3. We have shown for the first time that XeCl laser is effective for the treatment of vitiligo. 
4. The XeCl laser proved to be effective in the treatment of patch-stage MF. 
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7 Abbreviations 
UV: Ultraviolet 
PUVA: Psoralen plus ultraviolet A 
8-MOP: 8-methoxypsoralen 
BB-UVB: Broad-band ultraviolet B 
SUP: Selective UVB phototherapy 
NB-UVB: Narrow-band ultraviolet B 
AD: Atopic dermatitis 
MF: Mycosis fungoides 
XeCl: Xenon chloride 
IL: Interleukin 
IFN: Interferon 
ICAM: Intercellular adhesion molecule 
MLR: Mixed lymphocyte reaction 
MECLR: Mixed epidermal cell lymphocyte reaction 
PAF: Platelet-activating factor 
SCF: Stem cell factor 
IgE. Immunoglobulin E 
TH: T helper cell 
ECP: Extracorporeal photopheresis 
SDT: Skin directed therapy 
TNM: Tumor-node-metastasis 
RT: Radiotherapy 
TSEB: Total-skin electron-beam therapy 
MED: Minimal erythema dose 
LPSI: Local psoriasis severity index 
EASI: Eczema area severity index 
QL: Quality of life 
Phe: Phenylalanine 
PCR:. Polymerase chain reaction 
CTCL: Cutan T cell lymphoma 
TNF: Tumor necrosis factor 
FDA: Food and Drug Administration 
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